144例化疗致3~4级骨髓抑制的观察与分析

Clinical observation and analysis of chemotherapy induced grade 3~4 bone marrow suppression in 144 patients

目的分析化疗后3~4级骨髓抑制的特点。方法收集2019年~2020年因化疗致3~4级骨髓抑制的住院肿瘤患者共144例,对骨髓抑制特点及用药合理性进行回顾性分析。结果3~4级骨髓抑制患者中,61~70岁年龄患者所占比例最高。化疗方案以紫杉醇类联合铂类发生率居首位。骨髓抑制主要表现为中性粒细胞减少,为61.11%。结论多种因素可导致3~4级骨髓抑制,临床医师与药师应重点关注,同时在144例骨髓抑制处理上仍存在部分不合理之处,需进一步改进。

Objective To analyze the characteristics of grade 3~4 bone marrow suppression.Methods A total of 144 hospitalized tumor patients with grade 3~4 myelosuppression caused by chemotherapy from 2019 to 2020 were collected,and the characteristics of myelosuppression and the rationality of medication were analyzed retrospectively.Results Among patients with grade 3~4 myelosuppression,patients aged 61~70 years account for the highest proportion.The incidence of paclitaxel combined with platinum was the highest among chemotherapy regimens.Myelosuppression was mainly manifested by neutropenia(61.11%).Conclusion Many factors can lead to grade 3~4 myelosuppression,which should be paid special attention by clinicians and pharmacists.At the same time,there are still some unreasonable aspects in the treatment of 144 cases of myelosuppression,which need to be further improved.